West Pharmaceutical Services Introduces Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at the BIO International Convention

West Pharmaceutical Services, Inc. today announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022.

Daikyo Crystal Zenith® (CZ®) is a technologically advanced cyclic olefin polymer containment and delivery system that offers an alternative to glass, mitigating the risk of breakage and reducing the chance of particulates, contamination, and extractables.

The 2.25mL CZ Insert Needle Syringe System is an expansion upon the 1mL Insert Needle Syringe System offering. Until now, the syringe system has only been available in sizes up to 1mL, but the new 2.25mL size allows for larger volume injections. As market traction on larger dose injections grows, the new CZ syringe system size will help pharmaceutical companies to bring their product to patients in a safe and most user-centric model possible.

West Pharmaceutical Services Introduces Daikyo Crystal Zenith® 2.25Ml Insert Needle Syringe System At Bio International Convention
Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System

“By creating a larger fill volume in our high-quality CZ Insert Needle Syringe System, we’re able to answer the needs of more patients with a safe and reliable containment solution,” said Li Chen, VP and GM, Biologics at West. “Where patients previously may have needed multiple injections to achieve their dose, the 2.25mL Insert Needle Syringe System will allow for fewer or less frequent injections enabling an easier patient experience.”

West has partnered with Daikyo in an exclusive distributor arrangement to provide the CZ Insert Needle Syringe Systems syringe globally.

To learn more about the Daikyo CZ 2.25mL Insert Needle Syringe System, visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”